tbuckley/cabot-search huggingface dataset:
Sensitivity of fetal<i>RHD</i>screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands
Authors: Masja de Haas, Florentine F Thurik, Catharina P B van der Ploeg, Barbera Veldhuisen, Hoang Hirschberg, Aicha Ait Soussan, Heleen Woortmeijer, Frithjofna Abbink, Godelieve C M L Page-Christiaens, Peter G Scheffer, C Ellen van der Schoot
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To determine the accuracy of non-invasive fetal testing for the <i>RHD</i> gene in week 27 of pregnancy as part of an antenatal screening programme to restrict anti-D immunoglobulin use to women carrying a child positive for <i>RHD</i>. <b>Design</b>&nbsp;Prospectively monitoring of fetal <i>RHD</i> testing accuracy compared with serological cord blood typing on introduction of the test. Fetal <i>RHD</i> testing was performed with a duplex real time quantitative polymerase chain reaction, with cell-free fetal DNA isolated from 1 mL of maternal plasma The study period was between 4 July 2011 and 7 October 2012. The proportion of women participating in screening was determined. <b>Setting</b>&nbsp;Nationwide screening programme, the Netherlands. Tests are performed in a centralised setting. <b>Participants</b>&nbsp;25 789 RhD negative pregnant women. <b>Main outcome measures</b>&nbsp;Sensitivity, specificity, false negative rate, and false positive rate of fetal <i>RHD</i> testing compared with serological cord blood typing; proportion of technical failures; and compliance to the screening programme. <b>Results</b>&nbsp;A fetal <i>RHD</i> test result and serological cord blood result were available for 25 789 pregnancies. Sensitivity for detection of fetal <i>RHD</i> was 99.94% (95% confidence interval 99.89% to 99.97%) and specificity was 97.74% (97.43% to 98.02%). Nine false negative results for fetal <i>RHD</i> testing were registered (0.03%, 95% confidence interval 0.01% to 0.06%). In two cases these were due to technical failures. False positive fetal <i>RHD</i> testing results were registered for 225 samples (0.87%, 0.76% to 0.99%). Weak RhD expression was shown in 22 of these cases, justifying anti-D immunoglobulin use. The negative and positive predictive values were 99.91% (95% confidence interval 99.82% to 99.95%) and 98.60% (98.40% to 98.77%), respectively. More than 98% of the women participated in the screening programme. <b>Conclusions</b>&nbsp;Fetal <i>RHD</i> testing in week 27 of pregnancy as part of a national antenatal screening programme is highly reliable and can be used to target both antenatal and postnatal anti-D immunoglobulin use.
Additional surgical resection after endoscopic mucosal dissection for early gastric cancer: A medium-sized hospital's experience
Authors: Bunzo Nakata, Masashige Tendo, Masatsugu Okuyama, Kenichi Nakahara, Hirotaka Ishizu, Go Masuda, Tomohiro Lee, Takeshi Hori, Masahiko Ohsawa, Hiroshi Sato, Tetsuro Ishikawa
Journal: International Journal of Surgery (2016)
Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)
Authors: Roger M. Lyons, Sharon T. Wilks, David J. Friedman, Shelby A Young, Gail Brown
Journal: Blood (2012)
SAT0311 The Comparability of Patient and Physician Global Assessment in Early and Non-Early Systemic Lupus Erythematosus Patients
Authors: M. Pasali, V. Sadovici-Bobeica, M. Cebanu, V. Salaru, L. Mazur-Nicorici, M. Mazur
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To compare patient and physician global assessment of disease activity in patients with systemic lupus erythematosus (SLE) depending on disease duration. <h3>Methods</h3> In performed case-control study were included patients that fulfilled SLICC classification criteria, 2012. The research included two groups: patients with early SLE – first group (disease duration less than 24 months) and non-early SLE – second group (disease duration more than 24 months). Patient and physician global assessments (PGA and PhGA) were rated by 0 -100 numeric scale. We evaluated the concordance of PGA and PhGA in each group and compared the results between groups. <h3>Results</h3> A total of 72 SLE patients were analyzed. First group included 36 patients with a mean age 37.2±13.2 (range 18–67) years, 83.3% female and mean disease duration was 12±9.4 months. Mean PGA value were lower compared to PhGA values in this group (47.5±22.0 versus 49.1±21.0), but the difference wasn9t statistically significant (p&gt;0,05). The second group included also 36 patients, mean age was 43±10.6 (range 24–73) years, 91.7% female and mean disease duration was 120±50 months. Mean PGA value was also lower than mean PhGA in this group, but with a smaller discrepancy (50.0±19.7 versus 50.2±20.9, p&gt;0,01). The comparison of groups showed that in patients with early SLE the discordance between PGA and PhGA, is more important than in patients with longer disease duration. <h3>Conclusions</h3> The comparison of PGA and PhGA in patients with early SLE patients and ones with longer disease duration showed that patients early in disease duration tend to diminish PGA underestimating their general estate, but without statistically significant difference. In longer disease duration PGA and PhGA variables become similar, that suggest the patient9s better understanding of their disease and general estate. <h3>Disclosure of Interest</h3> None declared
Gene Expression Profiles in Myeloma: Ready for the Real World?
Authors: Raphael Szalat, Herve Avet-Loiseau, Nikhil C. Munshi
Journal: Clinical Cancer Research (2016)

Abstract Multiple myeloma is a plasma cell malignancy characterized by molecular and clinical heterogeneity. The outcome of the disease has been dramatically improved with the advent of new drugs in the past few years. However, even in this context of increasing therapeutic options, important challenges remain, such as accurately evaluating patients' prognosis and predicting sensitivity to specific treatments and drug combinations. Transcriptomic studies have largely contributed to help decipher multiple myeloma complexity, characterizing multiple myeloma subgroups distinguished by different outcomes. Microarrays and, more recently, RNA sequencing allow evaluation of expression of coding and noncoding genes, alternate splicing events, mutations, and novel transcriptome modifiers, providing new information regarding myeloma biology, prognostication, and therapy. In this review, we discuss the role and impact of gene expression profiling studies in myeloma. Clin Cancer Res; 22(22); 5434–42. ©2016 AACR. See all articles in this CCR Focus section, “Multiple Myeloma: Multiplying Therapies.”
FIP1L1-PDGFRalpha Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months.
Authors: Michela Rondoni, Emanuela Ottaviani, Pier Paolo Piccaluga, Stefania Paolini, Serena Merante, Daniela Cilloni, Michele Malagola, Michela Palmisano, Tiziana Grafone, Francesca Messa, Francesco Buccisano, Mario Tiribelli, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Michele Baccarani
Journal: Blood (2006)
Notes from the Field: Photokeratoconjunctivitis Outbreak Associated with Damaged Metal Halide Lamps — Maharashtra State, Western India, June 2016
Authors: Vijaykumar Wagh, Bhimashankar Jamadar, Manoj Murhekar
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

On June 13, 2016, the Pimpriraja Primary Health Center in Aurangabad district, Maharashtra State, in western India reported learning of approximately 90 persons with red eyes and blurred vision. One day earlier, the patients had attended a gathering in Zalta village to acknowledge the contributions of a local political leader. An investigation by the Field Epidemiology Training Program (FETP) and officials from the Integrated Disease Surveillance Program (IDSP) in Aurangabad district was initiated to estimate the magnitude of the outbreak and identify reasons for its occurrence. The investigators determined that 92 (12%) of the 750 attendees had symptoms of keratoconjunctivitis, and four of six metal halide lamps used for illumination were damaged.
A Randomized Crossover Study of High- and Standard-Dose Recombinant Factor VIIa for Treatment of Hemarthroses in Hemophiliacs with Inhibitors.
Authors: Elena Santagostino, Maria E. Mancuso, Angiola Rocino, Giacomo Mancuso, Francesco A. Scaraggi, Massimo Morfini, Filomena Daniele, Giovanni Barillari, Pier M. Mannucci
Journal: Blood (2005)
Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial
Authors: Marianne Sponer Muhlebach, Valeria Beckett, Elena Popowitch, Melissa B Miller, Arthur Baines, Nicole Mayer-Hamblett, Edith T Zemanick, Wynton C Hoover, Jill M VanDalfsen, Preston Campbell, Christopher H Goss
Journal: Thorax (2016)

<h3>Objective</h3> To evaluate microbiological effectiveness, that is, culture negativity of a non-blinded eradication protocol (Rx) compared with observation (Obs) in clinically stable cystic fibrosis participants with newly positive methicillin resistant <i>Staphylococcus</i><i>aureus</i> (MRSA) cultures. <h3>Design</h3> This non-blinded trial randomised participants ages 4–45 years with first or early (≤2 positive cultures within 3 years) MRSA-positive culture without MRSA-active antibiotics within 4 weeks 1:1 to Rx or Obs. The Rx protocol was: oral trimethoprim-sulfamethoxazole or if sulfa-allergic, minocycline plus oral rifampin; chlorhexidine mouthwash for 2 weeks; nasal mupirocin and chlorhexidine body wipes for 5 days and environmental decontamination for 21 days. The primary end point was MRSA culture status at day 28. <h3>Results</h3> Between 1 April 2011 to September 2014, 45 participants (44% female, mean age 11.5 years) were randomised (24 Rx, 21 Obs). At day 28, 82% (n=18/22) of participants in the Rx arm compared with 26% (n=5/19) in the Obs arm were MRSA-negative. Adjusted for interim monitoring, this difference was 52% (95% CI 23% to 80%, p&lt;0.001). Limiting analyses to participants who were MRSA-positive at the screening visit, 67% (8/12) in the Rx arm and 13% (2/15) in the Obs arm were MRSA-negative at day 28, adjusted difference: 49% (95% CI 22% to 71%, p&lt;0.001). Fifty-four per cent in the Rx arm compared with 10% participants in the Obs arm remained MRSA-negative through day 84. Mild gastrointestinal side effects were higher in the Rx arm. <h3>Conclusions</h3> This MRSA eradication protocol for newly acquired MRSA demonstrated microbiological efficacy with a large treatment effect. <h3>Trial registration number</h3> NCT01349192.
AB0241 Plasma Micro-RNAs Potentially Associated with The Increase Risk for Cardiovascular Disease in Rheumatoid Arthritis Patients
Authors: S. Paredes, D. Taverner, J.C. Vallve, R. Ferre, A. Castro, L. Masana
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) patients are at increased risk for cardiovascular diseases and an accelerated atherogenesis is considered the cause of this increase. MicroRNAs (miRs) are small, non-coding RNA molecules which negatively regulate gene expression. Plasmatic miRs have been identified as biomarkers in a wide range of cardiovascular diseases (CVD). <h3>Objectives</h3> To identify plasmatic miRs in RA patients that can facilitate earlier diagnosis of CVD and provide insight regarding the increase risk for CVD in these patients. <h3>Methods</h3> We compared plasmatic profiles of 754 miRs in 7 RA patients without CVD, in 7 patients with acute myocardial infarction (AMI) but without RA, and in 7 healthy controls with the objective to find miRs commonly expressed in the two groups of patients but at different levels from the controls. All participants were male and were matched for age and for classical cardiovascular risk factors. Plasma profile of miRs were analyzed by real time PCR using validated TaqMan® OpenArray® MicroRNA panels which enables the quantification of 754 human miRNAs. Differential expression was analyzed with Expression Suite software. Selected miRs were further analyzed with 2<sup>-DDct</sup> method. Kruskal-Wallis test and Dunns post- test were used for the statistical analyses. <h3>Results</h3> We were able to measure in the three groups, 50% (379) of the miRs represented in the array. Plasma profile of circulating miRs in RA and AMI patients were different from the controls. Plasma miRs that were commonly expressed in AR and AMI and expressed significantly different versus controls were: mir-Let-7a, miR-96, miR-381, miR-451, miR-518d, miR-425–5p, miR-572, miR-190b, miR-708, and miR1180. Interestingly, all 10 miRs were down-regulated compared with controls. Furthermore, 9 miRs were differentially expressed in AMI patients versus controls and 16 miRs in RA patients versus controls. <h3>Conclusions</h3> In the present study we have identified a group of 10 miRs that potentially can be involved in the increase risk for CVD seen in RA patients. Among all these miRs, miR-451 and Let-7a have been previously associated with CVD and it might be the best candidates for future validation studies. <h3>Disclosure of Interest</h3> None declared
High intensity statins are associated with greatest reduction in mortality
Authors: Jacqui Wise
Journal: BMJ (2016)

Patients with atherosclerotic cardiovascular disease who received the highest intensity statin treatment showed the greatest reductions in mortality, data from more than half a million patients have shown.1

The retrospective cohort analysis published in JAMA Cardiology showed that high intensity statins were associated with a small but significant survival advantage compared with moderate intensity statins, including among patients over 75 years.

The researchers examined one year cardiovascular mortality by intensity of statin therapy among 509 766 adults with atherosclerotic cardiovascular disease treated in the Veterans Affairs healthcare system. The average age of the patients was …
AB0161 Investigation of Oxidative Stress, Oxygenation and Erythema in Patients with Systemic Sclerosis, Primary Raynaud's Phenomenon and Undifferentiated Connective Tissue Disease and in Healthy Controls: Table 1.
Authors: I. Poxon, T.L. Moore, J.B. Manning, S. Leggett, M. Dickinson, A.L. Herrick, A.K. Murray
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic sclerosis (SSc) is a rare connective tissue disease characterised by skin fibrosis and microvascular dysfunction. Oxidative stress, hypoxia and ischaemia have previously been implicated in SSc pathogenesis. <h3>Objectives</h3> The aim of this study was to further elucidate the pathophysiology of different subtypes of Raynaud9s phenomenon (RP) by measuring oxidative stress, oxygenation and perfusion in patients with primary RP (PRP), undifferentiated connective tissue disease (UCTD), and SSc, comparing between groups and with healthy controls. Patients with UCTD were included to understand more about their early structural and functional changes as they are potentially an interim group between PRP and SSc. Our hypothesis was that oxidative stress would be increased in the UCTD and SSc groups and the oxygenation and perfusion would be decreased. <h3>Methods</h3> Measurements of oxidative stress, oxygenation and erythema (skin redness, an approximate, indirect measure of perfusion) were taken at a single point, at 9 sites, over the body using spectroscopy. Oxidative stress was measured as an increase in fluorescence induced by UV light. Oxygenation and erythema were calculated from white light reflection spectra. <h3>Results</h3> Measurements were taken from 53 healthy controls (HC), 36 female (f), median age 45, IQR [38–54] years; 20 patients with PRP, 17 f, 46 [39–52] years, duration of RP 8 [3–25] years; 37 patients with UCTD, 26 f, 43 [31–54] years, duration of RP 7 [5–16] years; 100 patients with SSc, 83 f, 59 [52–66] years, duration of RP 16 [8–24] years, duration of SSc 11 [4–18] years. A subset of data over the 9 sites is shown in Table 1. Oxidative stress was increased at all sites (statistically significant differences between groups [p&lt;0.05] at 7/9 sites) in patients with SSc as compared to HC. Oxygenation showed no trend. Erythema showed a trend of lower values at all sites for patients with SSc vs. HC (statistically significant at 7/9 sites). <h3>Conclusions</h3> Patients with SSc showed a trend towards increased oxidative stress and decreased erythema compared to HC as hypothesised, providing further evidence that both oxidative stress and ischaemia are associated with SSc. Oxygenation showed no trend, suggesting that oxygenation measurements may not be sensitive enough to detect differences or that oxygenation is not affected at baseline (i.e. it is functional rather than structural). Further studies may clarify whether incorporating a dynamic challenge (e.g. temperature change) would aid differentiation between groups. <h3>Acknowledgement</h3> Arthritis Research UK and EPSRC funded this study. <h3>Disclosure of Interest</h3> None declared
Retransplantation with Stem Cells from Mismatched Related Donors after Graft Rejection in Pediatric Patients.
Authors: Peter J. Lang, Johann Greil, Ingo Müller, Peter Bader, Thomas Klingebiel, Frank Heinzelmann, Claus Belka, Bernhard Kremens, Alfred Reiter, Paul G. Schlegel, Rupert Handgretinger
Journal: Blood (2006)
AB0520 Mortality in Systemic Lupus Erythematosus in A Argentinian Cohort
Authors: V. Juarez, M. Aciar, N. Cucchiaro, R. Rojas Tessel, E. Picco, E. Buschiazzo, M.V. Lencina, M.D.L.A. Aciar, I. Artes Rocha, M.E. Crespo Espindola
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease associated with a high morbidity and mortality. The specific causes of death may vary among ethnic groups. <h3>Objectives</h3> To examine mortality rates related to SLE in a single Argentinian population. <h3>Methods</h3> A retrospective cohort study was designed. Clinical Record of SLE patients treated between 2000 and 2005 and followed until 2015 in a tertiary no academical hospital that does not attend pediatric population were reviewed, including demografic and clinical data. The cause of death was searched from the medical records and deaths certificates from the Public Health Archives. Continuous data was expressed in median and interquartile range (IQR), categorical data in frequency and percentage. Chi-square test or Fisher9s test was used to analyse categorical data and Mann-Whitney or Student9s T-Test for continuous data. Kaplan – Meier survival curves were calculated. A p value &lt;0.05 was considered as significant. <h3>Results</h3> Fifty- five patients were enrolled, 48 women (87%), with a median age of 37 years (IQR:29–44.5), median disease duration of 9 years (IQR:3–12.3) and a total follow-up of 500 patients- years.Thirty- five patients (63%) were diagnoses after the first visit. Two (3.6%) were smokers, 16 (29.1%) had hypertension, 8 (14%) were diabetics and 9 (16.7%) has dyslipidemia. Treatments included glucocorticoids (&gt;10 mg/ day of prednisone) in 47 (85%), immunosuppressive therapy 27 (49.1%) and anti-malarial 44 (80%). Renal involvement was found in 30 (54%) patients. <h3>Conclusions</h3> Long-term survival in a single center of SLE argentinian patients was low in comparation with oteher studies. An cumulative survival from diagnosis of 81% at 5 years and 61% at 10 years was observed. Infection and SLE activity were the main causes of death <h3>Disclosure of Interest</h3> None declared
Functional Analysis of Phage Display Selected Single-Chain Variable Antibody Fragments (scFvs) Specific for Anti-FVIII Antibodies
Authors: Kerstin Brettschneider, Anja Naumann, Sonja Neimanis, Joerg Kahle, Christine Heller, Thomas Klingebiel, Dirk Schwabe, Christoph Koenigs
Journal: Blood (2014)
CEBP α Mutations in Childhood Acute Myeloid Leukemia.
Authors: Der-Cherng Liang, Lee-Yung Shih, Chein-Fuang Huang, Iou-Jih Hung, Chao-Ping Yang, Hsi-Che Liu, Tang-Her Jaing, Lin-Yen Wang, Wan-Hui Chang
Journal: Blood (2004)
THU0421 Serum-Based Soluble Markers May Differentiate Psoriatic Arthritis from Osteoarthritis
Authors: V. Chandran, A.V. Perruccio, S. Li, F. Abji, R. Gandhi, D.D. Gladman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It is often difficult to differentiate psoriatic arthritis (PsA) from osteoarthritis (OA) in clinical practice. <h3>Objectives</h3> To aid clinical diagnosis, we aimed to identify soluble biomarkers that differentiate PsA from OA. <h3>Methods</h3> Serum samples from 201 patients with OA (mean age 65 years, 43.3% males, no history of inflammatory disease), 77 patients with PsA satisfying CASPAR criteria (mean age 45 years, 54.5% males) and 76 healthy controls (mean age 37 years, 50% males) were obtained from the respective biobanks of the Arthritis Program, University Health Network, and the University of Toronto PsA Program. Samples were obtained at the time of joint replacement surgery (OA) or at the time of clinical assessment (PsA, healthy controls), and stored at -80°C until laboratory assays were conducted. Soluble markers of cartilage metabolism (COMP, hyaluronan), metabolic syndrome (adiponectin, adipsin, resistin, HGF, insulin, leptin) and inflammation/immune response (CRP, IL-1b, -6, -8, TNF-α, MCP-1, NGF) were assayed in the samples using Luminex multiplex assay. Marker levels in serum were compared across the 3 groups using the Kruskal-Wallis test. Pair-wise comparisons were made with Wilcoxon rank sum test. To identify markers that differentiate PsA from OA, multivariate logistic regression analyses with backward elimination, adjusted for age and sex, were constructed using markers determined to be significant at a p≤0.1 from univariate analyses. Discriminative ability was assessed by way of receiver operating characteristic (ROC) curves based on findings from multivariate models. The final model was further validated in an independent set of 73 PsA and 75 OA samples using predicted probabilities estimated using coefficients from the model developed on the training set. <h3>Results</h3> Univariate analyses revealed the following markers significantly differed across groups (p&lt;0.001): COMP, hyaluronan; resistin, HGF, insulin, leptin; CRP, IL -6, -8, TNF-α, MCP-1, NGF. When comparing PsA to OA, the following markers significantly differed (p&lt;0.001): COMP, hyaluronan; resistin, HGF, insulin; CRP, IL-6, -8, TNF-α, MCP-1, NGF. Multivariate analysis demonstrated that COMP (OR 1.24, 95% CI 1.06, 1.46), resistin (OR 1.26, 95% CI 1.07, 1.48), MCP-1 (OR 1.10, 95% CI 0.07, 1.48) and NGF (OR &lt;0.001, 95% CI &lt;0.001, 0.25) were independently associated with PsA vs. OA. The area under the ROC curve (AUROC) for this model was 0.99. Internal cross-validation of the model consistently identified MCP-1 as a PsA marker. Further validation of the model including COMP, resistin, MCP-1 and NGF showed an AUROC of 0.98. <h3>Conclusions</h3> A panel of 4 biomarkers (COMP, resistin, MCP-1, NGF) may distinguish PsA from OA. Clinical utility of these markers will need to be determined in prospective studies. <h3>Disclosure of Interest</h3> None declared